Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Trial Results
Biotech
ASH: Novartis details ianalumab's phase 3 rare blood disease win
If the combo therapy's boosted platelet counts persist even longer, it could "change the treatment paradigm" for primary immune thrombocytopenia.
Darren Incorvaia
Dec 9, 2025 7:30am
Merck mulls PV program’s future while Takeda takes victory lap
Dec 8, 2025 4:30pm
Dyne readies FDA push after DMD exon 51 med excels in trial
Dec 8, 2025 10:50am
Capricor sets up 2nd DMD approval attempt with ph. 3 win
Dec 3, 2025 11:11am
Cogent eyes FDA approval after clearing another ph. 3 hurdle
Nov 10, 2025 10:57am
BridgeBio's calcium deficiency candidate scores phase 3 win
Oct 29, 2025 7:00am
